Floatz logo

HUMAN PERIPHERAL BLOOD LEUKOCYTES

Ovarian Carcinoma

A2 Biotherapeutics Inc.Cell therapyActive
D
30/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
15/ 100
Competitive Position
81/ 100

Competitive context

244 Active assets in the Ovarian Carcinoma cohort.

Asset / SponsorPhaseRating
Trabectedin
AGO Research GmbH
Phase 4BBB
Mirvetuximab Soravtansine
AstraZeneca
Phase 3BBB
Olaparib
Imunon
Phase 4BB
Irinotecan
OHSU Knight Cancer Institute
Phase 2BB
Carboplatin
University of Washington
Phase 3BB

View all 50 →

Same molecule, other indications

HUMAN PERIPHERAL BLOOD LEUKOCYTES is also rated in:

Auto Stem Cell TransplantDormant
B
Indicative ·
57 / 100
View asset →
CAR T Cell TherapyDormant
B
Indicative ·
57 / 100
View asset →
large B-cell lymphomaDormant
CCC
Indicative ·
54 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →